AstraZeneca: Capital Group discloses 5.017815% voting stake

AstraZeneca PLC has published a Form 6-K reporting a TR-1 notification of major holdings.

Rhea-AI Filing Summary

AstraZeneca PLC has published a Form 6-K reporting a TR-1 notification of major holdings. The Capital Group Companies, Inc. has crossed the 5% disclosure threshold in AstraZeneca’s voting rights. The group now holds a total of 77,811,893 voting rights, representing 5.017815% of AstraZeneca’s voting rights.

These voting rights are held indirectly through shares in two lines: common stock with ISIN GB0009895292 accounting for 4.239936% of voting rights, and depository receipts with ISIN US0463531089 accounting for 0.777879%. The position was previously 4.997854%, so this notice reflects a small increase above the 5% reporting threshold.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What major shareholding was disclosed in AstraZeneca (AZN) on this Form 6-K?

The filing reports that The Capital Group Companies, Inc. has notified AstraZeneca that it now holds 77,811,893 voting rights, representing 5.017815% of AstraZeneca’s voting rights, crossing the 5% major shareholding threshold.

How many AstraZeneca voting rights does Capital Group now control?

Capital Group’s notified holding amounts to 77,811,893 voting rights in AstraZeneca PLC, corresponding to 5.017815% of the company’s total voting rights.

How is Capital Group’s AstraZeneca (AZN) stake split between common stock and depository receipts?

The position is held via two lines: AstraZeneca common stock with ISIN GB0009895292 representing 4.239936% of voting rights, and depository receipts with ISIN US0463531089 representing 0.777879% of voting rights.

Did Capital Group’s percentage holding in AstraZeneca recently change?

Yes. The notification shows the resulting situation at 5.017815% of voting rights, compared with a previous position of 4.997854%, indicating a modest increase that moved the holding above the 5% threshold.

Does Capital Group hold any AstraZeneca voting rights through financial instruments?

No financial instruments are reported. The tables for financial instruments (sections 8B1 and 8B2) show no voting rights or percentages, indicating the notified position is based on voting rights attached to shares only.

Who are the controlled undertakings linked to The Capital Group Companies, Inc. in this AstraZeneca holding?

The notification lists several controlled undertakings under The Capital Group Companies, Inc., including Capital Research and Management Company, Capital International, Inc., Capital Group Private Client Services, Inc., Capital International Sarl, and Capital International Limited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/17/2025 - 12:52 PM EST Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November 2025 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Holding(s) in Company

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB0009895292

Issuer Name

ASTRAZENECA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City of registered office (if applicable)

Los Angeles

Country of registered office (if applicable)

USA

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

13-Nov-2025

6. Date on which Issuer notified

15-Nov-2025

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	5.017815	0.000000	5.017815	77811893
Position of previous notification (if applicable)	4.997854	0.000000	4.997854

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB0009895292 Common Stock		65749228		4.239936
US0463531089 Depository Receipt		12062665		0.777879
Sub Total 8.A	77811893		5.017815%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
The Capital Group Companies, Inc.	Capital Research and Management Company
The Capital Group Companies, Inc.	Capital International, Inc.
The Capital Group Companies, Inc.	Capital Group Private Client Services, Inc.
The Capital Group Companies, Inc.	Capital International Sarl
The Capital Group Companies, Inc.	Capital International Limited

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of six investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl, Capital International K.K., Capital Group Private Client Services Inc, and Capital Group Investment Management Private Limited. CGII management companies primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based registered investment adviser and an affiliated federally chartered bank.Neither CGC nor any of its affiliates own shares of the Issuer for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

12. Date of Completion

15-Nov-2025

13. Place Of Completion

Los Angeles

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 17 November 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary